Equity valuations for Sana Biotechnology have faced downward pressure due to ongoing investor concerns regarding the company's limited cash runway, high cash burn rates associated with early-stage clinical trials, and the looming risk of equity dilution. Although its scientific pipeline targeting cell and gene therapies shows long-term promise, pre-revenue biotechnology firms remain exceptionally sensitive to market sentiment, macroeconomic funding costs, and quarterly expenditure reports.